Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies. UROFIT Study.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be included after signing the informed consent. Within 12 months after mini-invasive procedure, subjects are identified, contacted by phone/email, or invited to attend during the regular scheduled follow-up visit. If this is not possible, patients will be asked to schedule a special interview to assess possible participation in the study. During follow-up or unscheduled visit, the subsequent information will be collected through a questionnaire that contains several socio-demographic and anamnestic questions. During subsequent visit, PROFFIT and EORTC QLQ-C30 questionnaires will be administered to patients. Post-operative complications are reported using the Clavien-Dindo classification. Anamnestic and socio-demographic information will be collected through a generic self-designed questionnaire including the following data: age, sex, residence (within or outside the Veneto region), marital status (married, divorced, cohabiting, single, widowed), employment status (employed, unemployed, retired), presence of dependents (yes/no), level of education (defined as primary, middle or high school, university degree), concomitant pathologies. Additional data on the oncological history are also reported: histology and staging of the disease, presence or absence of metastatic disease, additional treatments before or after surgery (e.g. neoadjuvant treatments, adjuvant treatments, radiotherapy).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
View:

• Male or female ≥ 18 years of age;

• ECOG PS 0-1

• Diagnosis of urological neoplasm (prostate, bladder and kidney cancer) treated with robotic surgery (robot-assisted prostatectomy, robot-assisted radical cystectomy, robot-assisted radical or partial nephrectomy) in the last twelve months;

• Subjects willing to sign informed consent.

Locations
Other Locations
Italy
Istituto Oncologico Veneto
RECRUITING
Padua
Contact Information
Primary
Antonio Amodeo, MD
antonio.amodeo@iov.veneto.it
0423421321
Backup
Giuliana Lista, MD
giuliana.lista@iov.veneto.it
0423421321
Time Frame
Start Date: 2025-06-18
Estimated Completion Date: 2026-06
Participants
Target number of participants: 120
Treatments
PROFFIT and EORTC QLQ-C30 questionnaires
Sponsors
Leads: Istituto Oncologico Veneto IRCCS

This content was sourced from clinicaltrials.gov

Similar Clinical Trials